Free Trial
NASDAQ:ENLV

Enlivex Therapeutics Q1 2024 Earnings Report

Enlivex Therapeutics logo
$0.95 0.00 (-0.42%)
As of 03:39 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Enlivex Therapeutics EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.25
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Enlivex Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Enlivex Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, June 13, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

Enlivex Therapeutics' Q1 2025 earnings is scheduled for Friday, June 13, 2025, with a conference call scheduled on Thursday, June 12, 2025 at 6:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Enlivex Therapeutics Earnings Headlines

Enlivex Therapeutics (NASDAQ:ENLV) Trading Down 4% - Time to Sell?
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Enlivex Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enlivex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enlivex Therapeutics and other key companies, straight to your email.

About Enlivex Therapeutics

Enlivex Therapeutics (NASDAQ:ENLV), together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

View Enlivex Therapeutics Profile

More Earnings Resources from MarketBeat